Article Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients with Mild Alzheimer's Disease or Mild Cognitive Impairment

This is a phase I, an open label, single dose, and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.


Post a question or thought about this dataset here.